Amylyx Pharmaceuticals Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim Anderson from Bank of America Securities reiterated a Buy rating on the stock and has a $16.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson’s rating is based on several strategic factors that position Amylyx Pharmaceuticals Inc favorably for future growth. The company recently raised $175 million, which extends its cash runway into 2027 and provides financial flexibility to support its ongoing and upcoming projects. This capital infusion allows Amylyx to invest in commercial activities and advance its pipeline, particularly with the pivotal Phase 3 LUCIDITY trial for avexitide, expected to yield results in the first half of 2026.
Furthermore, the company is on track to complete enrollment for this trial and aims to provide a regulatory update on AMX0035 by the end of 2025. The analyst’s valuation is primarily driven by the potential success of avexitide, with additional upside possible from AMX0035 if it progresses successfully through Phase 3 trials. These factors, combined with the company’s strategic initiatives and financial health, underpin the Buy rating and the increased price objective of $16.
In another report released on September 16, Goldman Sachs also maintained a Buy rating on the stock with a $20.00 price target.
AMLX’s price has also changed dramatically for the past six months – from $3.780 to $13.290, which is a 251.59% increase.